Foghorn Therapeutics to Participate in Prominent Investor Conferences
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a pioneering biotechnology firm, is gearing up for exciting opportunities to share its innovative advancements in medicine. The company focuses on transformative treatments that aim to correct abnormal gene expression and address serious health challenges. This conference season, Foghorn's management team will actively engage at three distinguished events: the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and the Jefferies 2025 London Healthcare Conference.
Participation Overview
At these significant gatherings, Foghorn Therapeutics will present its groundbreaking work in oncology. The management team, led by President and CEO Adrian Gottschalk, is set to lead discussions and participate in one-on-one meetings with investors.
Guggenheim Second Annual Healthcare Innovation Conference
The event kicks off with a fireside chat scheduled for Monday, November 10, at 11:00 a.m. ET. This will provide an opportunity to delve deeper into Foghorn's innovative strategies and its commitment to transforming the landscape of cancer treatment.
Stifel 2025 Healthcare Conference
Later, Foghorn will present at the Stifel 2025 Healthcare Conference on Thursday, November 13, at 4:00 p.m. ET. This presentation will showcase the company’s Gene Traffic Control® platform and its potential to revolutionize drug development.
Jefferies 2025 London Healthcare Conference Highlights
Foghorn Therapeutics will conclude its conference participation with a fireside chat at the Jefferies 2025 London Healthcare Conference on Wednesday, November 19, at 10:30 a.m. GMT. This event underscores Foghorn's commitment to sharing its vision with a global audience.
Accessible Presentations
Investors and stakeholders can access a webcast of the presentations following the events. These will be available under the “Events & Presentations” section on the company’s website for a duration of 90 days, ensuring that all interested parties have the opportunity to gain insights into Foghorn's pioneering work.
About Foghorn Therapeutics
Foghorn Therapeutics is at the forefront of biotechnology with a mission to develop a novel class of medicines that specifically target genetically determined dependencies within the chromatin regulatory system. By leveraging its proprietary Gene Traffic Control® platform, the company meticulously studies, identifies, and validates potential drug targets. This approach is particularly focused on addressing unmet needs in oncology where traditional treatments often fall short.
Future Prospects
As Foghorn continues to expand its pipeline of product candidates, the company remains committed to addressing serious diseases through innovative solutions. The management team strongly believes that their research will not only unveil new therapeutic options but also enhance patient outcomes across various disease spectrums.
Contact Information
For more details about Foghorn Therapeutics and its latest advancements, individuals can reach out to Karin Hellsvik via email at khellsvik@foghorntx.com.
Frequently Asked Questions
What will Foghorn Therapeutics present at the conferences?
Foghorn will highlight its Gene Traffic Control® platform and its potential to revolutionize treatments for oncology.
Who is presenting for Foghorn Therapeutics?
Adrian Gottschalk, the President and CEO, will lead the presentations and fireside chats.
When will the conferences take place?
The conferences are scheduled for November 10, November 13, and November 19.
How can I access the presentations?
Presentations can be accessed via the company’s website under the "Events & Presentations" section.
What is Foghorn's focus area in research?
Foghorn Therapeutics focuses on developing innovative medicines targeting genetically determined dependencies, primarily in the field of oncology.